Kaneda H - Search Results

1

Large cell neuroendocrine carcinoma of the mediastinum with alpha-fetoprotein production.

Takezawa K, Okamoto I, Fukuoka J, Tanaka K, Kaneda H, Uejima H, Yoon HE, Imakita M, Fukuoka M, Nakagawa K. Takezawa K, et al. Among authors: kaneda h. J Thorac Oncol. 2008 Feb;3(2):187-9. doi: 10.1097/JTO.0b013e3181623359. J Thorac Oncol. 2008. PMID: 18303442 Free article.

2

Early diagnosis of hepatocellular carcinoma with lectin electrophoresis of serum alpha-fetoprotein.

Taga H, Hirai H, Ishizuka H, Kaneda H. Taga H, et al. Among authors: kaneda h. Tumour Biol. 1988;9(2-3):110-5. doi: 10.1159/000217551. Tumour Biol. 1988. PMID: 2456597

3

Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.

Kurata T, Tamura K, Kaneda H, Nogami T, Uejima H, Asai Go Go, Nakagawa K, Fukuoka M. Kurata T, et al. Among authors: kaneda h. Ann Oncol. 2004 Jan;15(1):173-4. doi: 10.1093/annonc/mdh006. Ann Oncol. 2004. PMID: 14679138 Free article. No abstract available.

4

Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer.

Kurata T, Tamura K, Yamamoto N, Nogami T, Satoh T, Kaneda H, Nakagawa K, Fukuoka M. Kurata T, et al. Among authors: kaneda h. Br J Cancer. 2004 Jun 1;90(11):2092-6. doi: 10.1038/sj.bjc.6601817. Br J Cancer. 2004. PMID: 15150564 Free PMC article. Clinical Trial.

5

Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.

Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Kaneda H, et al. Lung Cancer. 2004 Nov;46(2):247-54. doi: 10.1016/j.lungcan.2004.04.032. Lung Cancer. 2004. PMID: 15474673

6

A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients.

Kaneda H, Kurata T, Tamura K, Uejima H, Nakagawa K, Fukuoka M. Kaneda H, et al. Anticancer Res. 2006 May-Jun;26(3B):2479-85. Anticancer Res. 2006. PMID: 16821636 Free article. Clinical Trial.

7

SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion.

Tanaka K, Arao T, Maegawa M, Matsumoto K, Kaneda H, Kudo K, Fujita Y, Yokote H, Yanagihara K, Yamada Y, Okamoto I, Nakagawa K, Nishio K. Tanaka K, et al. Among authors: kaneda h. Int J Cancer. 2009 Mar 1;124(5):1072-80. doi: 10.1002/ijc.24065. Int J Cancer. 2009. PMID: 19065654

8

Epidermal growth factor receptor lacking C-terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor.

Maegawa M, Arao T, Yokote H, Matsumoto K, Kudo K, Tanaka K, Kaneda H, Fujita Y, Ito F, Nishio K. Maegawa M, et al. Among authors: kaneda h. Cancer Sci. 2009 Mar;100(3):552-7. doi: 10.1111/j.1349-7006.2008.01071.x. Epub 2009 Jan 14. Cancer Sci. 2009. PMID: 19154417 Free PMC article.

9

EGFR mutation up-regulates EGR1 expression through the ERK pathway.

Maegawa M, Arao T, Yokote H, Matsumoto K, Kudo K, Tanaka K, Kaneda H, Fujita Y, Ito F, Nishio K. Maegawa M, et al. Among authors: kaneda h. Anticancer Res. 2009 Apr;29(4):1111-7. Anticancer Res. 2009. PMID: 19414352 Free article.

10

mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.

Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N, Nishio K. Matsumoto K, et al. Among authors: kaneda h. Cancer Res. 2009 Sep 15;69(18):7160-4. doi: 10.1158/0008-5472.CAN-09-1289. Epub 2009 Sep 8. Cancer Res. 2009. PMID: 19738050

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

612 results

Search Page

Filters